Hepatitis Medicines

Chronic hepatitis C infection can cause serious liver problems such as scarring (cirrhosis), or liver cancer.The combination of Resof Total works by stopping the virus that causes hepatitis C from spreading inside the body.

Dr. Reddy’s Laboratories Limited Sofosbuvir and Velpatasvir is used to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. It may sometimes be used with another antiviral medication (ribavirin).

Resof Total ( Sofosbuvir 400 mg & velpatasvir 100 mg) is used alone or with ribavirin to treat chronic hepatitis C. Sofosbuvir is in a class of antiviral medications called nucleotide hepatitis C virus (HCV) NS5B polymerase inhibitors. Velpatasvir is in a class of antiviral medications called HCV NS5A replication complex inhibitors.

The combination of Resof Total works by stopping the virus that causes hepatitis C from spreading inside the body.

We assurance of quality and distribution anywhere in the world as per the buyer’s requirements.

We are not online Pharmacy, Resof Total is a prescription medication pharmaceutical drug that legally requires a medical prescription to be dispensed.

Please contact us for more Details, On How To Buy this Resof Total on Valid Prescription and On availability in Delhi & all over India.
Resof Total is a prescription drug that can be purchased by a patient only against a valid prescription of a healthcare professional like Gastroenterologist, Hepatologist or a Physician.

Common side effects may include:

A headache, Tired Feeling, Nausea, Diarrhea or Sleep Problems (Insomnia).

Call your doctor at once if you have:

Slow Heartbeats, Weak or Shallow Breathing; or low red blood cells-pale skin, weakness, rapid heart rate and trouble concentrating.

If you also take amiodarone: Seek medical help right away if you feel weak, tired, or light-headed, or if you have chest pain, shortness of breath, confusion, or memory problems.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.

Product Details:

Strength/Dose (in mg or ml)sofosbuvir 400 mg and velpatasvir 100 mgPack Size28 TabProduct TypeFinish Product

Indication:

Sofosbuvir With Velpatasvir is a two-drug combination for the treatment of hepatitis C. It is administered as a single daily pill containing the viral NS5A inhibitor velpatasvir and sofosbuvir, a nucleotide inhibitor of the viral RNA polymerase. It is the first treatment, that works for all genotypic, and is taken entirely by mouth. A single tablet regimen is used for adults with genotype 1-6 chronic hepatitis C virus (HCV) infection.

Mechanism of action:

Sofosbuvir With Velpatasvir is an oral fixed-dose combination of sofosbuvir, a nucleotide analog NS5B polymerase inhibitor and velapatasvir, an NS5A complex inhibitor. Sofosbuvir is approved for the treatment of genotype 1, 2, 3 and 4 HCV infection with different regimens and durations dependent on the HCV genotype. Velpatasvir (formerly GS-5816) is a novel NS5A inhibitor that has potent invitro anti-HCV activity across all genotypes at the picomolar level. The combination of sofosbuvir-velpatasvir is the first once-daily single-tablet regimen with pangenotypic activity.

Dosage and Administration:

Sofosbuvir With Velpatasvir is available as a coformulated, once-daily single-pill combination of sofosbuvir 400 mg and velpatasvir 100 mg. The recommended dose is one tablet once daily, taken with or without food.

Renal Impairment: For patients with mild to moderate renal impairment, no dosage adjustment of sofosbuvir-velpatasvir is recommended. There are insufficient data regarding the safety and efficacy of sofosbuvir-velpatasvir in patients with severe renal impairment (eGFR less than 30 ml/min/1.73m2) or end-stage renal disease requiring hemodialysis. Accordingly, no dosage recommendation has been given for patients with severe renal impairment or end-stage renal disease requiring dialysis.

Hepatic Impairment: For patients with mild, moderate, or severe hepatic impairment (Child-Pugh Class A, B, or C), no dosage adjustment for sofosbuvir-velpatasvir is recommended. For patients with decompensated cirrhosis who are receiving sofosbuvir-velpatasvir and ribavirin, clinical and laboratory monitoring is recommended.

Precaution:

Risk of Serious Symptomatic Bradycardia When Sofosbuvir Is Coadministered with Amiodarone and Another HCV Direct Acting Antiviral: Amiodarone is not recommended for use with Sofosbuvir With Velpatasvir due to the risk of symptomatic bradycardia, particularly in patients also taking beta blockers or with underlying cardiac comorbidities and/or with advanced liver disease. In patients without alternative, viable treatment options, cardiac monitoring is recommended. Patients should seek immediate medical evaluation if they develop signs or symptoms of bradycardia.

Risk of Reduced Therapeutic Effect Due to Concomitant Use of Sofosbuvir With Velpatasvir with P-gp Inducers and/or Moderate to Potent Inducers of CYP2B6, CYP2C8 or CYP3A4: Rifampin, St. John’s wort, and carbamazepine are not recommended for use with Sofosbuvir With Velpatasvir as they may significantly decrease sofosbuvir and/or velpatasvir plasma concentrations.